Literature DB >> 6808912

Trapping of nonhydrolyzable cephalosporins by cephalosporinases in Enterobacter cloacae and Pseudomonas aeruginosa as a possible resistance mechanism.

R L Then, P Angehrn.   

Abstract

Resistance to cefotaxime (CTA) and ceftriaxone (CTR) in Enterobacter cloacae and Pseudomonas aeruginosa was investigated in several strains which are susceptible or resistant to these agents. All strains produced a chromosomally mediated cephalosporinase of the Richmond type 1. beta-Lactamases in susceptible strains were inducible, whereas resistant strains produced the enzymes constitutively. CTA and CTR were very poor substrates but potent inhibitors of all enzymes. Binding to, rather than hydrolysis by, beta-lactamases was assumed to be a major reason for resistance, and combination experiments supported this assumption. Dicloxacillin, which did not inhibit the growth and which was a poor inducer but a strong inhibitor of these beta-lactamases, exerted strong synergistic activity when combined with CTA or CTR in strains which produced large amounts of beta-lactamase constitutively. Cefoxitin, on the other hand, poorly active alone, but a good inducer, strongly antagonized CTA or CTR in susceptible strains producing inducible enzymes. In marked contrast to CTA and CTR were the findings with cefsulodin. Cefsulodin was active against CTA- and CTR-resistant Pseudomonas, and its activity was hardly influenced by dicloxacillin or cefoxitin. Since cefsulodin was found to have a very low affinity for all cephalosporinases, these findings corroborate the assumption that binding of nonhydrolyzable cephalosporins, rather than hydrolysis by cephalosporinases, may play an important role in resistance to these agents and other newer cephalosporins in Enterobacteriaceae, as well as in other gram-negative bacteria.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6808912      PMCID: PMC181998          DOI: 10.1128/AAC.21.5.711

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  28 in total

1.  beta-lactamase stability of HR 756, a novel cephalosporin, compared to that of cefuroxime and cefoxitin.

Authors:  K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

2.  Beta-lactamase assays.

Authors:  G W Ross; C H O'Callaghan
Journal:  Methods Enzymol       Date:  1975       Impact factor: 1.600

3.  Clavulanic acid: a beta-lactamase-inhiting beta-lactam from Streptomyces clavuligerus.

Authors:  C Reading; M Cole
Journal:  Antimicrob Agents Chemother       Date:  1977-05       Impact factor: 5.191

4.  Mechanism of synergistic effects of beta-lactam antibiotic combinations on gram-negative bacilli.

Authors:  W E Farrar; J K Newsome
Journal:  Antimicrob Agents Chemother       Date:  1973-08       Impact factor: 5.191

Review 5.  The beta-lactamases of gram-negative bacteria and their possible physiological role.

Authors:  M H Richmond; R B Sykes
Journal:  Adv Microb Physiol       Date:  1973       Impact factor: 3.517

6.  Inhibition of beta-lactamases by beta-lactam antibiotics.

Authors:  C O'Callaghan; A Morris
Journal:  Antimicrob Agents Chemother       Date:  1972-12       Impact factor: 5.191

7.  CP-45,899, a beta-lactamase inhibitor that extends the antibacterial spectrum of beta-lactams: initial bacteriological characterization.

Authors:  A R English; J A Retsema; A E Girard; J E Lynch; W E Barth
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

8.  The demonstration and significance of synergism between -lactam antibiotics.

Authors:  J M Hamilton-Miller
Journal:  J Med Microbiol       Date:  1971-05       Impact factor: 2.472

9.  Emergence of resistance to cefamandole: possible role of cefoxitin-inducible beta-lactamases.

Authors:  C C Sanders; W E Sanders
Journal:  Antimicrob Agents Chemother       Date:  1979-06       Impact factor: 5.191

10.  Iodometric assay method for beta-lactamase with various beta-lactam antibiotics as substrates.

Authors:  T Sawai; I Takahashi; S Yamagishi
Journal:  Antimicrob Agents Chemother       Date:  1978-06       Impact factor: 5.191

View more
  68 in total

Review 1.  Remarks on the screening of antibiotics for antibacterial activity.

Authors:  O Zak; H Mett; T O'Reilly
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-07       Impact factor: 3.267

2.  In vitro investigation of BK-218, a new oral and parenteral cephalosporin.

Authors:  I Szabó; J Barabás; A Tar; L Kiss; M Filep; T Schmidt; K Marossy; B Tóth-Martinez; G Barabás; F Hernádi
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

Review 3.  Resistance to third generation cephalosporins: the current situation.

Authors:  J C Pechère
Journal:  Infection       Date:  1989 Sep-Oct       Impact factor: 3.553

4.  Preferential hydrolysis of cis configuration compounds at the 3,4 position of monobactams by beta-lactamase from Morganella morganii.

Authors:  K Matsuda; M Sanada; S Nakagawa; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

5.  What do beta-lactamases mean for clinical efficacy?

Authors:  H C Neu
Journal:  Infection       Date:  1983       Impact factor: 3.553

6.  Occurrence and expression of imipemide (N-formimidoyl thienamycin) resistance in clinical isolates of coagulase-negative staphylococci.

Authors:  R M Blumenthal; R Raeder; C D Takemoto; E H Freimer
Journal:  Antimicrob Agents Chemother       Date:  1983-07       Impact factor: 5.191

7.  Increased amounts of a novel penicillin-binding protein in a strain of methicillin-resistant Staphylococcus aureus exposed to nafcillin.

Authors:  H F Chambers; B J Hartman; A Tomasz
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

Review 8.  Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  D M Richards; R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

9.  Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens.

Authors:  H Knothe; P Shah; V Krcmery; M Antal; S Mitsuhashi
Journal:  Infection       Date:  1983 Nov-Dec       Impact factor: 3.553

Review 10.  Cefepime clinical pharmacokinetics.

Authors:  M P Okamoto; R K Nakahiro; A Chin; A Bedikian
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.